Uncovering the evolutionary history of bacterial endosymbiosis in opportunistic fungal pathogens of humans

Active Project Grant Awarded Last action

Award ID
R21AI180695
Recipient
Awarding agency
Obligated
$787,043

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 83% complete
Originally
Place of performance
Ithaca, NY 14853, USA

Award details come from USAspending.gov.

Description

Abstract
The goal of this exploratory work is to elucidate the evolutionary history of symbiotic associations between the mucoromycotina fungi and their endosymbiotic bacteria (EB), focusing on population-level processes, including fungal adaptation to human hosts and contributions of shared 6-methyladenine (6MA) DNA epigenetic modifications as means of communication between the partners. We expect that this work will establish foundations for future treatment of mucormycoses, which are human infections caused by mucoromycotina. Mucormycoses are increasingly frequent, highly destructive, and often fatal in immune-compromised individuals. While bacteria-free asymbiotic mucoromycotina are responsible for many infections, EB are often detected in clinical isolates and known to affect mucoromycotina virulence in humans. Therefore, elucidating population-level processes that govern these mucoromycotina-EB symbioses is important for developing novel mucoromycosis therapies. One of the mechanisms contributing to the establishment and maintenance of such symbioses may be sharing of 6MA DNA modifications by mucoromycotina and bacteria. Importantly, these modifications and the contributing enzymes are nearly absent from mammals and potentially could be targeted by pharmacological inhibitors for mucormycosis therapy. To test the hypothesis that EB manipulate their fungal hosts through epigenomic reprogramming, we propose functional characterization of candidate bacterial symbiosis factors, including adenine-specific DNA methyltransferases. To gain insights into population-level processes shaping fungal-bacterial symbioses, we plan to conduct a population genomic study of a model fungal-bacterial symbiosis complemented by a population-level analysis of genome-wide 6MA modification and transcriptional landscapes in fungi differing in the symbiotic status and source of isolation (natural versus clinical settings). Expected outcomes of the project include insights into population-level processes, including fungal adaptation to mammalian hosts and the role of epigenetic reprogramming in the initiation and functioning of fungal- bacterial symbioses important for human health as well as 6MA methylome data for a leading causal agent of mucormycosis. The findings are expected to be instrumental in developing future mucormycosis therapies relying on 6MA DNA modification inhibitors.

Transactions

Action Obligated Date
Amendment $0
Amendment $148,002
Amendment $22,036
Amendment $22,036
Amendment $198,323
Amendment $198,323
Original award $198,323

Subawards

Subrecipient Amount Awarded
The Regents Of The University Of California The scope of work for LBNL relevant to this project is exploration of population-level epigenomic data. To complement traditional pan-genome analysis produced… $81,825

Quick answers

Who received award R21AI180695?

R21AI180695 was awarded to Cornell University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 12, 2024.

How much is award R21AI180695 worth?

$787,043 has been obligated on R21AI180695.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award